SCHEMBL3570864

SCHEMBL3570864

N#Cc1cnc2oc(-c3ccccc3)c(-c3ccccc3)c2c1N1CCN(CCn2ccnc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
HSD17B10 Q99714 6/20 0.48
KDM4E B2RXH2 5/20 0.48
USP2 O75604 5/20 0.48
HPGD P15428 5/20 0.48
TSHR P16473 5/20 0.48
NPSR1 Q6W5P4 4/20 0.48
MAPK1 P28482 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 3/20 0.48
AURKA O14965 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
LCK P06239 10/20 0.48
TNK2 Q07912 10/20 0.48
KDR P35968 9/20 0.48
JAK3 P52333 8/20 0.48
HTT P42858 2/20 0.43
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559066 0.82 ALDH1A1 (0.42) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL3566434 0.79 ALDH1A1 (0.58) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL5256772 0.73 AURKA (0.48) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL3573421 0.70 KDM4E (0.45) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL3566479 0.70 KDM4E (0.53) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL3568195 0.70 KDM4E (0.51) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL3572103 0.69 KDM4E (0.52) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL3572129 0.68 LCK (0.65) ALDH1A1HSD17B10KDM4EUSP2HPGD
SCHEMBL13462029 0.67 TNK2 (0.48) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL3562506 0.67 TNK2 (0.55) ALDH1A1HSD17B10KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 ALDH1A1 869/4885HSD17B10 3253/4885KDM4E 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.